In Focus channel feed – Endpoints News

SIGN UP

In focus channel feed

After falling behind the leaders, dissed by some experts, biotech showman Patrick Soon-Shiong finally gets his Covid-19 vaccine ready for a trial. But can it live up to the hype?

11 months ago

Endpoints News ranks the top 57 players in the Covid-19 vaccine race. Here's how it stacks up today

Last year

After Big Pharma abandoned infectious diseases, 5 biotech contrarians decided to go all in. Then Covid-19 changed everything

Last year

After psilocybin and ketamine, a new biotech comes along developing a drug Scott Gottlieb fought

Last year

Chinese vaccine developers have begun to shed some secrecy around Covid-19 candidates. What do we know?

Last year

Why Merck waited, and what they now bring to the Covid-19 fight

Last year

Alnylam, Sarepta jump into Covid-19 game, as pandemic rekindles antiviral hopes of RNA-targeting technology

Last year

Banking on hope, swayed by hype? Hydroxychloroquine in the time of Covid-19

Last year

Creative or unethical? Researchers’ Covid-19 GoFundMe campaign spurs critics

Last year

Natural killers are coming for Covid-19 and the therapy, experts say, could make things worse

Last year

‘If grippe condemns, the secondary infections execute’: What the coronavirus pandemic means for the field of antibiotics

Last year

Investing in the time of coronavirus: the good, the bad and the hopeful, as biotech VC firms close funds worth $3B

Last year

‘It’s like the tortoise and the hare’: A pandemic puts Sanofi’s $600M bet to the test

Last year

'Dramatic times': How did an $8B surge in NIH grants over five years change research on the ground (if at all)?

Last year

A 9/11-era Omaha facility, an old Ebola drug, and the ubiquitous Dr. Fauci: Inside the first US novel coronavirus trial

Last year

For two decades, a new vaccine technology has been slowly approaching prime time. Now, can it stop a pandemic?

Last year

He built a MERS treatment in 6 months and then the best Ebola drug. Now Christos Kyratsous turns his sights on Covid-19

Last year

Carl June on CRISPR, CAR–T and how the Vietnam War dropped him into medicine

Last year

Can we make the antibiotic market great again?

Last year

At #JPM20, two CEOs, two radically different therapies, and a fight to chase down sickle cell

Last year

#JPM20: After a year of NASH collapses, all eyes on two biotechs

Last year

Over a decade into the milestone boom, it's time to ask. Just how often do they really pay off?

Last year

Alzheimer's breakthrough? Not so fast — experts poke holes in data underlying China's surprise approval

Last year

Path to the top: What kind of experience does it take to get tapped for the helm of a biotech?

3 years ago

First page Previous page 123 Next page Last page